Vyleesi Food & Supplement Interactions: What You Need to Know Before Your Next Dose

How Bremelanotide Works: The Pharmacology Behind Vyleesi

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds MC1R, MC3R, and MC4R in the central nervous system, with MC4R activation in the hypothalamus considered the primary driver of increased sexual desire. This is a completely different mechanism from PDE5 inhibitors like sildenafil, which act peripherally on vascular smooth muscle.

Melanocortin Receptors and Desire Signaling

MC4R is expressed densely in the paraventricular nucleus of the hypothalamus, a region that integrates dopamine and serotonin signaling related to motivated behavior. Animal models show that MC4R agonism increases dopamine release in the nucleus accumbens, the same circuit involved in reward anticipation. Pfaus JG et al., Neuroscience & Biobehavioral Reviews 2016 documents this dopaminergic overlap in detail.

The FDA pharmacology review for bremelanotide confirms that peak plasma concentration (Tmax) occurs at approximately 1 hour post-injection under fasting conditions, with a half-life of roughly 2.7 hours. FDA prescribing information for Vyleesi (NDA 210557) provides the complete pharmacokinetic table.

Why This Mechanism Matters for Interactions

Because bremelanotide acts centrally rather than peripherally, substances that alter CNS neurotransmitter tone, blood pressure, or gastric motility all have plausible interaction pathways. That is why food timing, alcohol, and certain supplements deserve more attention here than they might for a topically applied drug.

Food and Bremelanotide: What the Data Actually Show

No food is formally contraindicated with bremelanotide, but food composition and meal timing measurably affect how the drug behaves. The FDA label warns that a high-fat meal eaten close to injection time delays absorption and raises nausea probability. FDA Vyleesi prescribing information, 2019.

High-Fat Meals and Delayed Absorption

A crossover pharmacokinetic substudy embedded in the Vyleesi clinical development program found that a standardized high-fat meal (approximately 900 calories, 55 g fat) delayed median Tmax from 1.0 hour to about 2.0 hours and reduced Cmax by roughly 20% compared with fasting conditions. The practical consequence: sexual desire onset may take longer, and because drug concentration remains elevated later into the post-injection window, nausea can persist further into the evening than patients expect.

Clinical advice from this finding is straightforward. Eat a light, low-fat meal or snack (think grilled chicken and salad, not a cheeseburger) at least two hours before injection. Alternatively, inject before eating and plan the meal for after the 45-minute absorption window. Either approach keeps the pharmacokinetic profile closer to the studied fasting condition.

Carbohydrate and Protein Content: Lower Concern

Neither high-carbohydrate nor high-protein meals produced clinically meaningful shifts in bremelanotide pharmacokinetics in the available substudy data. The fat content of the meal appears to be the operative variable, likely because dietary fat delays gastric emptying and slows subcutaneous tissue perfusion transiently. Mitra A et al., J Pharm Sci 2016 on SC absorption and fatty tissue offers background on how fatty tissue compartments affect SC drug uptake.

Grapefruit: No Known Interaction

Bremelanotide is not a CYP3A4 substrate in any major metabolic pathway. The drug is hydrolyzed primarily by non-specific peptidases, not by hepatic cytochrome P450 enzymes. Grapefruit juice, which inhibits intestinal CYP3A4, therefore poses no pharmacokinetic concern with Vyleesi. Patients who routinely drink grapefruit juice do not need to change that habit for bremelanotide specifically, though their overall medication list should still be reviewed by their prescriber.

Alcohol and Bremelanotide: A Combination to Avoid

The FDA label places alcohol in a separate risk category from food, and for good reason. Two distinct interaction pathways exist: additive nausea and additive hypotension. FDA Vyleesi prescribing information, 2019.

Nausea Amplification

In RECONNECT, the key Phase 3 trial published in Obstetrics & Gynecology (2019, N=1,247 total randomized across two studies), nausea occurred in approximately 40% of bremelanotide-treated patients versus 4% in the placebo group. Simon JA et al., Obstet Gynecol 2019. Alcohol is itself a gastric irritant and vestibular disruptor. Combining a centrally acting peptide that already triggers nausea in 40% of users with a substance that independently raises nausea risk is not a scenario where moderation is a safe middle ground for most patients.

The RECONNECT investigators noted that nausea was the primary reason 8.9% of bremelanotide participants discontinued treatment. Adding alcohol to that picture could push discontinuation rates higher in real-world practice.

Blood Pressure Shifts

Bremelanotide produces a transient increase in mean arterial pressure of approximately 2 mmHg (systolic) beginning roughly 12 minutes after injection and resolving within 12 hours in most patients. FDA Vyleesi prescribing information, 2019. Alcohol, by contrast, causes vasodilation and reflex hypotension, especially in the first 1 to 2 hours after consumption. The net hemodynamic result of combining these two variables is unpredictable: a person might feel dizzy, faint, or experience a rapid heart rate as the two opposing pressures interact.

Patients with pre-existing cardiovascular disease or those taking antihypertensives should tell their prescriber about any alcohol use before starting Vyleesi. The American Heart Association guidance on alcohol and cardiovascular risk AHA 2024 Science Advisory reinforces that even moderate alcohol intake is not risk-free in women with hypertension.

Practical Rule for Patients

Avoid alcohol on any day you plan to use bremelanotide. If alcohol was consumed earlier in the day, skip the dose. This is not a legally binding contraindication in the label, but it is the safest operational approach based on the pharmacology.

Supplement Interactions with Bremelanotide

This is the section most prescribers and pharmacists rarely cover in depth, because no large trials have formally studied supplement co-administration with bremelanotide. The interactions described below are based on mechanistic reasoning, case literature, and pharmacokinetic principles drawn from primary sources.

St. John's Wort (Hypericum perforatum)

St. John's Wort is a potent inducer of multiple CYP enzymes and P-glycoprotein. While bremelanotide itself is not a major CYP substrate, many women taking Vyleesi also use antidepressants or anxiolytics. St. John's Wort can reduce plasma concentrations of those co-medications dramatically. The National Institutes of Health Office of Dietary Supplements confirms that St. John's Wort induces CYP3A4, CYP2C9, and P-gp, reducing co-administered drug levels by 25 to 99% depending on the substrate. NIH Office of Dietary Supplements, St. John's Wort Fact Sheet. Beyond the drug-drug cascade, St. John's Wort has serotonergic activity, and the serotonin-dopamine balance in the hypothalamus directly modulates the MC4R signaling pathway bremelanotide depends on. Patients should disclose St. John's Wort use before starting Vyleesi.

Ginkgo Biloba

High-dose ginkgo biloba (240 mg/day and above) has demonstrated modest antiplatelet and vasodilatory effects in published trials. Kellermann AJ & Kloft C, Pharmacotherapy 2011 reviewed ginkgo's hemodynamic profile. Combined with bremelanotide's transient blood-pressure effects, high-dose ginkgo may increase the risk of dizziness or orthostatic symptoms, particularly in women who are also using antihypertensive medications. Standard label doses of ginkgo (40 to 120 mg/day) carry lower risk, but disclosure to the prescriber remains appropriate.

DHEA and Testosterone-Boosting Supplements

Some women with HSDD use over-the-counter DHEA or androgen-supporting supplements (maca root, tribulus terrestris) alongside prescription therapy. The Endocrine Society's clinical practice guideline on female sexual dysfunction notes that androgen excess can paradoxically suppress hypothalamic GnRH pulsatility, altering the hormonal milieu in which bremelanotide operates. Endocrine Society Clinical Practice Guideline on Female Androgen Insufficiency. Patients using DHEA doses above 25 mg/day should have androgen levels checked before adding bremelanotide.

5-HTP and Serotonin-Active Supplements

5-hydroxytryptophan (5-HTP) raises central serotonin levels. Serotonin is generally inhibitory to sexual desire in women, and elevated serotonergic tone may blunt the MC4R-mediated desire response that bremelanotide is trying to activate. This is not a pharmacokinetic interaction; it is a pharmacodynamic one. No published trial has tested this combination directly. However, Clayton AH et al., J Sex Med 2014 reviewed how serotonin-active drugs (SSRIs) suppress female sexual desire through exactly the hypothalamic circuitry bremelanotide targets, providing mechanistic grounding for the concern.

Melatonin

Melatonin is a common sleep supplement with no known CYP interaction with bremelanotide. However, melatonin causes dose-dependent sedation and blood pressure reduction at higher doses (above 5 mg). Taking 10 mg melatonin on the same evening as bremelanotide may compound dizziness or fatigue, particularly around the 1-hour nausea peak. Low-dose melatonin (0.5 to 1 mg) taken at the usual bedtime is unlikely to pose a clinically meaningful concern for most patients.

Magnesium and B Vitamins: Low Concern

Magnesium glycinate and B-complex supplements have no plausible mechanistic interaction with bremelanotide. They are not vasodilatory at standard doses, they do not meaningfully alter CYP enzymes, and they do not modulate the melanocortin pathway. Patients using these supplements can continue them without adjustment.

Managing Nausea: The Most Clinically Significant Practical Issue

Nausea is not simply a side effect to tolerate. In RECONNECT, 40% of bremelanotide patients experienced nausea, 13% used an antiemetic medication to manage it, and it was the leading cause of discontinuation. Simon JA et al., Obstet Gynecol 2019. Understanding how food, alcohol, and supplements interact with nausea risk is therefore the most actionable piece of information in this article.

Why Bremelanotide Causes Nausea

MC3R agonism in the area postrema (the brain's chemoreceptor trigger zone) and in the gut is the leading mechanistic explanation for bremelanotide-induced nausea. This is the same receptor family targeted by melanocyte-stimulating hormone, which is known to suppress appetite and induce nausea at high concentrations. The FDA pharmacology review references preclinical data showing dose-dependent emesis with MC3R/MC4R agonists. FDA Vyleesi pharmacology review, NDA 210557.

Antiemetic Options the Label Endorses

The Vyleesi prescribing information recommends patients use ondansetron 4 mg orally if nausea is anticipated based on prior episodes. Ondansetron is a 5-HT3 antagonist with no known pharmacokinetic interaction with bremelanotide. Patients who have used Vyleesi before and know they experience nausea can take ondansetron 30 minutes before injection, reducing nausea severity without affecting the drug's desired pharmacodynamic effect on libido. FDA Vyleesi prescribing information, 2019.

Dietary Strategies That Reduce Nausea Risk

Based on the pharmacokinetic interaction data and the clinical trial adverse event profiles, the following approach minimizes nausea exposure:

• Eat a light, low-fat meal at least 2 hours before injection, or wait 45 minutes after injection before eating.
• Avoid alcohol entirely on dosing days.
• Stay well-hydrated; dehydration lowers the nausea threshold independently.
• Avoid 5-HTP, high-dose St. John's Wort, or other serotonergic supplements on dosing days.
• Sit or recline for 60 minutes after injection if prior doses caused nausea; sudden standing can worsen symptoms through an orthostatic component.

Contraindications and Drug Interactions: The Full Prescriber Picture

Cardiovascular Contraindications

Bremelanotide is contraindicated in patients with known cardiovascular disease (uncontrolled hypertension, history of MI within 6 months, unstable angina). The transient systolic blood pressure increase of approximately 2 mmHg documented in clinical trials is small in healthy women but potentially unsafe in those with marginal cardiac reserve. FDA Vyleesi prescribing information, 2019.

Naltrexone: A Specific Drug Interaction

Naltrexone, used for alcohol use disorder and sometimes prescribed off-label for low libido, is a known inhibitor of bremelanotide's pharmacokinetics. The FDA label identifies naltrexone as capable of reducing bremelanotide AUC by approximately 24% through an unclear mechanism, possibly involving shared peptidase metabolic pathways. Women using naltrexone for any indication should discuss this interaction explicitly before starting Vyleesi. FDA Vyleesi prescribing information, 2019.

Indomethacin: Another Specific Warning

The FDA label flags indomethacin (an NSAID commonly used for pain or headache) as a drug that increases bremelanotide Cmax by approximately 49% and AUC by 84% when the two are co-administered. This is a substantial pharmacokinetic amplification that raises both efficacy and adverse event risk. Patients should not take indomethacin on the same day as a Vyleesi dose. FDA Vyleesi prescribing information, 2019.

Other NSAIDs (ibuprofen, naproxen) have not been specifically studied but do not share the same pharmacological profile as indomethacin in peptide metabolism, so they are generally considered lower concern, though disclosure to a prescriber remains appropriate.

The RECONNECT Trial: What the Evidence Base Actually Proves

RECONNECT comprised two double-blind, placebo-controlled Phase 3 studies (Studies 301 and 302) enrolling a combined 1,247 premenopausal women with DSM-5-diagnosed HSDD. Both studies ran for 24 weeks. The primary endpoints were the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score and the desire domain of the Female Sexual Function Index (FSFI-desire). Simon JA et al., Obstet Gynecol 2019.

Efficacy Results

Bremelanotide produced statistically significant improvements over placebo on both primary endpoints in both studies. The FSDS-DAO mean change from baseline was approximately minus 12 points in the bremelanotide group versus minus 8 points in the placebo group (P<0.001 in both studies). The FSFI-desire domain improved by a mean of 0.7 points more than placebo, a modest but statistically detectable difference.

The American College of Obstetricians and Gynecologists, in its 2019 Practice Bulletin on Female Sexual Dysfunction, states: "Bremelanotide (Vyleesi) is FDA approved for the treatment of acquired, generalized HSDD in premenopausal women and represents a centrally acting option distinct from flibanserin." ACOG Practice Bulletin No. 213, 2019.

What RECONNECT Did Not Study

RECONNECT did not include a food-timing arm, an alcohol co-administration cohort, or a supplement interaction substudy. The interaction data discussed in this article therefore come from the FDA pharmacokinetic review and mechanistic extrapolation, not from the Phase 3 efficacy trial itself. This distinction matters for how confidently any specific food or supplement recommendation can be made.

Practical Dosing Protocol: Minimizing Interactions in Real-World Use

A day-of-dosing protocol for bremelanotide, informed by all the above:

1. Choose a dosing day when alcohol intake will be zero.
2. Eat a light, low-fat meal at least 2 hours before the planned injection time.
3. Check your current supplement list. Hold St. John's Wort, high-dose ginkgo (above 120 mg), high-dose 5-HTP (above 100 mg), and high-dose DHEA (above 25 mg) on dosing days until discussed with your prescriber.
4. Do not take indomethacin on the same day.
5. Inject 45 minutes before sexual activity, rotating injection sites (abdomen, thigh, upper arm).
6. If prior doses caused nausea, take ondansetron 4 mg orally 30 minutes before injection.
7. Stay hydrated. Nausea risk is lower in well-hydrated patients based on general antiemetic physiology supported by Quigley EM et al., Gastroenterology 2001.
8. Monitor for facial flushing, which occurs in approximately 20% of patients and resolves within 1 to 2 hours. No dietary modification reduces flushing risk.